Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 19, 2024
Discovery & Translation

Science Spotlight: Platelets as targeted protein degraders 

BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Oct 31, 2024
Discovery & Translation

Science Spotlight: Macrophage-fibroblast cross-talk in heart failure

BioCentury’s roundup of translational innovations also includes synthetic gene regulators, three longevity genes and more
BioCentury | Mar 30, 2024
Discovery & Translation

Combining ADCs with protein degraders could widen the therapeutic windows of both

Degrader-antibody conjugates double up on selectivity, but ‘DACs’ present optimization challenge
BioCentury | Feb 24, 2024
Discovery & Translation

Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more

BioCentury’s roundup of translational innovations
BioCentury | Oct 7, 2022
Discovery & Translation

Galixir’s rapid PROTAC design; plus Engimmune’s TCR platform and more

BioCentury’s roundup of translational news
BioCentury | Mar 4, 2022
Distillery Therapeutics

A dual BRD4-EP300 inhibitor for pancreatic cancer

BioCentury | Sep 25, 2021
Translation in Brief

Verve’s durable PCSK9 base editor; plus Novartis, PureTech and more

BioCentury’s roundup of translational news
BioCentury | Aug 27, 2021
Distillery Therapeutics

Androgen receptor isoform for spinal and bulbar muscular atrophy

BioCentury | Aug 18, 2021
Emerging Company Profile

Ranok: a chaperone-based approach to targeted degradation

Emerging Company Profile: Ranok has raised $40M to test whether alternative to PROTACs could have safety, dosing advantages
BioCentury | Aug 5, 2021
Deals

Aug. 5 Quick Takes: Kite, Appia working on allogeneic CAR-iNKTs

Plus: Sierra Oncology-AZ, Valneva, Regeneron and more
Items per page:
1 - 10 of 143